8:01AM ShangPharma purchases Shanghai in-vivo drug research facility from Charles River (CRL) (SHP) 29.64 : Co announces it has, through its main Chinese subsidiary, Shanghai ChemPartner, acquired the assets in Charles River Laboratories' (CRL) Shanghai research facility. As part of the transaction, ShangPharma will take over Charles River's lease for the facility, which will provide the co with an additional 2,972 square meters.
surf's up......crikey
Market Data 
Markets 
AI
